Advertisement

Drugs & Aging

, Volume 34, Issue 4, pp 255–264 | Cite as

Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients

  • Sizheng Zhao
  • Fred Otieno
  • Asan Akpan
  • Robert J. Moots
Review Article

Abstract

Complementary and alternative medicines (CAMs) are widely used by patients with rheumatoid arthritis (RA); however, a significant proportion of these patients do not inform their physicians. This has many potential implications in a group of predominantly elderly patients with altered pharmacokinetics, comorbidities and polypharmacy of potentially toxic drugs. CAM usage may affect compliance and pharmacokinetics of conventional therapy for RA and comorbidities; therefore, physicians should engage patients in dialogues regarding CAM usage. This review introduces common CAMs used by RA patients, such as herbal remedies, supplements, and fish and plant oils, and their potential impact on conventional therapy. Efficacy of these treatments are not reviewed in detail but references for reviews and trials are provided for further reading. Fish oils and vitamin D supplementation may generally be recommended, while thunder god vine should be avoided. Patients should also be made aware of the risks of contamination and adulteration of less reputable sources of CAMs, and directed to evidence-based sources of information. Physicians should acknowledge the limitations of scientific evidence and not be prejudiced or dogmatic; however, they should remain resolute against therapies that are known to be ineffective or unsafe.

Keywords

Rheumatoid Arthritis Rheumatoid Arthritis Patient Tocilizumab Triptolide Andrographolide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Author contributions

Sizheng Zhao wrote the manuscript with substantial contributions from Fred Otieno, Asan Akpan and Robert J. Moots.

Compliance with Ethical Standards

Conflict of interest

Sizheng Zhao, Fred Otieno, Asan Akpan and Robert J. Moots have no conflicts of interest to declare.

Funding

No funding was received for this review.

References

  1. 1.
    National Center for Complementary and Alternative Medicine. What is CAM. 2012. Available at: https://nccih.nih.gov/sites/nccam.nih.gov/files/D347_05-25-2012.pdf. Accessed 30 Sept 2016.
  2. 2.
    Nahin RL, Dahlhamer JM, Taylor BL, Barnes PM, Stussman BJ, Simile CM, et al. Health behaviors and risk factors in those who use complementary and alternative medicine. BMC Public Health. 2007;7:217.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yen L, Jowsey T, McRae IS. Consultations with complementary and alternative medicine practitioners by older Australians: results from a national survey. BMC Complement Altern Med. 2013;13:73.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ernst E, Posadzki P. Complementary and alternative medicine for rheumatoid arthritis and osteoarthritis: an overview of systematic reviews. Curr Pain Headache Rep. 2011;15(6):431–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Tamhane A, McGwin G Jr, Redden DT, Hughes LB, Brown EE, Westfall AO, et al. Complementary and alternative medicine use in African Americans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(2):180–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Alarcon GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin N Am. 1995;21(3):589–604.Google Scholar
  7. 7.
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Tarner IH, Muller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv. 2008;5(9):1027–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology. 2012;51(Suppl 5):v22–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29(5):305–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Buchbinder R, Gingold M, Hall S, Cohen M. Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Intern Med J. 2002;32(5–6):208–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med. 1999;131(6):409–16.CrossRefPubMedGoogle Scholar
  13. 13.
    Geisler CC, Cheung CK. Complementary/alternative therapies use in older women with arthritis: Information sources and factors influencing dialog with health care providers. Geriatr Nurs. 2015;36(1):15–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheung C, Geisler C, Sunneberg J. Complementary/alternative medicine use for arthritis by older women of urban-rural settings. J Am Assoc Nurse Pract. 2014;26(5):273–80.PubMedGoogle Scholar
  15. 15.
    Hill C, Gill TK, Appleton S, Cleland LG, Taylor AW, Adams RJ. The use of fish oil in the community: results of a population-based study. Rheumatology. 2009;48(4):441–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. 2010;68(5):280–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Fortin PR, Lew RA, Liang MH, Wright EA, Beckett LA, Chalmers TC, et al. Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. J Clin Epidemiol. 1995;48(11):1379–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology. 2008;47(5):665–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704.CrossRefPubMedGoogle Scholar
  20. 20.
    Cleland LG, Caughey GE, James MJ, Proudman SM. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J Rheumatol. 2006;33(10):1973–9.PubMedGoogle Scholar
  21. 21.
    Cobb CS, Ernst E. Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin Rheumatol. 2006;25(3):275–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Sub Cell Biochem. 2008;49:133–43.CrossRefGoogle Scholar
  23. 23.
    Nordstrom DC, Honkanen VE, Nasu Y, Antila E, Friman C, Konttinen YT. Alpha-linolenic acid in the treatment of rheumatoid arthritis. A double-blind, placebo-controlled and randomized study: flaxseed vs. safflower seed. Rheumatol Int. 1995;14(6):231–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Korkina L, Kostyuk V, De Luca C, Pastore S. Plant phenylpropanoids as emerging anti-inflammatory agents. Mini Revi Med Chem. 2011;11(10):823–35.CrossRefGoogle Scholar
  25. 25.
    Brzeski M, Madhok R, Capell HA. Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1991;30(5):370–2.CrossRefPubMedGoogle Scholar
  26. 26.
    Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med. 1993;119(9):867–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol. 1994;33(9):847–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2011;(2):CD002948.Google Scholar
  29. 29.
    Wang X, Lin H, Gu Y. Multiple roles of dihomo-gamma-linolenic acid against proliferation diseases. Lipids Health Dis. 2012;11:25.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Moudgil KD, Berman BM. Traditional Chinese medicine: potential for clinical treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10(7):819–22.CrossRefPubMedGoogle Scholar
  31. 31.
    Tsang IK. Establishing the efficacy of traditional Chinese medicine. Nat Clin Pract Rheumatol. 2007;3(2):60–1.CrossRefPubMedGoogle Scholar
  32. 32.
    Gu WZ, Chen R, Brandwein S, McAlpine J, Burres N. Isolation, purification, and characterization of immunosuppressive compounds from tripterygium: triptolide and tripdiolide. Int J Immunopharmacol. 1995;17(5):351–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Canter PH, Lee HS, Ernst E. A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis. Phytomedicine. 2006;13(5):371–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Medicines and Healthcare products and Regulatory Agency. The MHRA issues warning over traditional Chinese medicines containing Lei Gong Teng (Tripterygium wilfordii). 2014. Available at: http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Herbalmedicines/Herbalsafetyupdates/Allherbalsafetyupdates/CON123310. Accessed 30 Sept 2016.
  35. 35.
    Mur E, Hartig F, Eibl G, Schirmer M. Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol. 2002;29(4):678–81.PubMedGoogle Scholar
  36. 36.
    Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, et al. A systematic screening of total antioxidants in dietary plants. J Nutr. 2002;132(3):461–71.PubMedGoogle Scholar
  37. 37.
    Willich SN, Rossnagel K, Roll S, Wagner A, Mune O, Erlendson J, et al. Rose hip herbal remedy in patients with rheumatoid arthritis—a randomised controlled trial. Phytomedicine. 2010;17(2):87–93.CrossRefPubMedGoogle Scholar
  38. 38.
    Larsen E, Kharazmi A, Christensen LP, Christensen SB. An antiinflammatory galactolipid from rose hip (Rosa canina) that inhibits chemotaxis of human peripheral blood neutrophils in vitro. J Nat Prod. 2003;66(7):994–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. Nutrition. 1996;12(4):274–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Winther K, Apel K, Thamsborg G. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol. 2005;34(4):302–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients?—a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2008;16(9):965–72.CrossRefPubMedGoogle Scholar
  42. 42.
    Burgos RA, Hancke JL, Bertoglio JC, Aguirre V, Arriagada S, Calvo M, et al. Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clin Rheumatol. 2009;28(8):931–46.CrossRefPubMedGoogle Scholar
  43. 43.
    Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum. 2001;44(11):2531–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Srivastava KC, Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses. 1992;39(4):342–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med. 2009;15(8):891–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res. 1980;71:632–4.PubMedGoogle Scholar
  47. 47.
    Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif. 2006;39(2):147–55.CrossRefPubMedGoogle Scholar
  48. 48.
    Biegert C, Wagner I, Ludtke R, Kotter I, Lohmuller C, Gunaydin I, et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. J Rheumatol. 2004;31(11):2121–30.PubMedGoogle Scholar
  49. 49.
    Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;(2):CD002946.Google Scholar
  50. 50.
    Matsuno H, Nakamura H, Katayama K, Hayashi S, Kano S, Yudoh K, et al. Effects of an oral administration of glucosamine-chondroitin-quercetin glucoside on the synovial fluid properties in patients with osteoarthritis and rheumatoid arthritis. Biosci Biotechnol Biochem. 2009;73(2):288–92.CrossRefPubMedGoogle Scholar
  51. 51.
    Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27(3):213–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Lems WF, Dijkmans BA. Should we look for osteoporosis in patients with rheumatoid arthritis? Ann Rheum Dis. 1998;57(6):325–7.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66(9):1137–42.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bala S, Shah B, Rajput P, Rao P. Unmasking of primary hyperparathyroidism by Vitamin D therapy. Indian J Nephrol. 2015;25(6):377–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Roubenoff R, Roubenoff RA, Selhub J, Nadeau MR, Cannon JG, Freeman LM, et al. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum. 1995;38(1):105–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Huang SC, Wei JC, Wu DJ, Huang YC. Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. Eur J Clin Nutr. 2010;64(9):1007–13.CrossRefPubMedGoogle Scholar
  57. 57.
    Chiang EP, Selhub J, Bagley PJ, Dallal G, Roubenoff R. Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther. 2005;7(6):R1404–11.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med. 1983;309(8):445–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Canter PH, Wider B, Ernst E. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. Rheumatology. 2007;46(8):1223–33.CrossRefPubMedGoogle Scholar
  60. 60.
    Casimiro L, Barnsley L, Brosseau L, Milne S, Robinson VA, Tugwell P, et al. Acupuncture and electroacupuncture for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2005;(4):CD003788.Google Scholar
  61. 61.
    Brosseau L, Robinson V, Wells G, Debie R, Gam A, Harman K, et al. Low level laser therapy (classes I, II and III) for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2005;(4):CD002049.Google Scholar
  62. 62.
    Brosseau LU, Pelland LU, Casimiro LY, Robinson VI, Tugwell PE, Wells GE. Electrical stimulation for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2002;(2):CD003687.Google Scholar
  63. 63.
    Cramp F, Hewlett S, Almeida C, Kirwan JR, Choy EH, Chalder T, et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2013;(8):CD008322.Google Scholar
  64. 64.
    Gok Metin Z, Ozdemir L. The effects of aromatherapy massage and reflexology on pain and fatigue in patients with rheumatoid arthritis: a randomized controlled trial. Pain Manag Nurs. 2016;17(2):140–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Fisher P, Scott DL. A randomized controlled trial of homeopathy in rheumatoid arthritis. Rheumatology. 2001;40(9):1052–5.CrossRefPubMedGoogle Scholar
  66. 66.
    Hagen KB, Byfuglien MG, Falzon L, Olsen SU, Smedslund G. Dietary interventions for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;(1):CD006400.Google Scholar
  67. 67.
    Diaz-Borjon A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26(4):273–93.CrossRefPubMedGoogle Scholar
  68. 68.
    McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163–84.CrossRefPubMedGoogle Scholar
  69. 69.
    Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;343:1–19.Google Scholar
  70. 70.
    Sandoval DM, Alarcon GS, Morgan SL. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol. 1995;34(Suppl 2):49–56.CrossRefPubMedGoogle Scholar
  71. 71.
    Patel DN, Low WL, Tan LL, Tan MM, Zhang Q, Low MY, et al. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore pharmacovigilance database from 1998 to 2009. Clin Toxicol. 2012;50(6):481–9.CrossRefGoogle Scholar
  72. 72.
    Ventola CL. Current issues regarding complementary and alternative medicine (CAM) in the United States: part 2. Regulatory and safety concerns and proposed governmental policy changes with respect to dietary supplements. P T. 2010;35(9):514–22.Google Scholar
  73. 73.
    Rice DC. Neurotoxicity of lead, methylmercury, and PCBs in relation to the Great Lakes. Environ Health Perspect. 1995;103(Suppl 9):71–87.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337–51.CrossRefPubMedGoogle Scholar
  75. 75.
    Setty AR, Sigal LH. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005;34(6):773–84.CrossRefPubMedGoogle Scholar
  76. 76.
    Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290(11):1500–4.CrossRefPubMedGoogle Scholar
  78. 78.
    Murakami Y, Tanaka T, Murakami H, Tsujimoto M, Ohtani H, Sawada Y. Pharmacokinetic modelling of the interaction between St John’s wort and ciclosporin A. Br J Clin Pharmacol. 2006;61(6):671–6.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Yang SY, Juang SH, Tsai SY, Chao PD, Hou YC. St. John’s wort significantly increased the systemic exposure and toxicity of methotrexate in rats. Toxicol Appl Pharmacol. 2012;263(1):39–43.CrossRefPubMedGoogle Scholar
  80. 80.
    Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004;38(1):50–2.CrossRefPubMedGoogle Scholar
  81. 81.
    Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2008;28(4):540–8.CrossRefPubMedGoogle Scholar
  82. 82.
    Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000;34(12):1478–82.CrossRefPubMedGoogle Scholar
  83. 83.
    He CL, Yi PF, Fan QJ, Shen HQ, Jiang XL, Qin QQ, et al. Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-kappaB signaling pathways in LPS-treated rat cardiac microvascular endothelial cells. Immunopharmacol Immunotoxicol. 2013;35(2):215–24.CrossRefPubMedGoogle Scholar
  84. 84.
    Yoopan N, Thisoda P, Rangkadilok N, Sahasitiwat S, Pholphana N, Ruchirawat S, et al. Cardiovascular effects of 14-deoxy-11,12-didehydroandrographolide and Andrographis paniculata extracts. Planta Med. 2007;73(6):503–11.CrossRefPubMedGoogle Scholar
  85. 85.
    Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. 2008;47(6):924–5.CrossRefPubMedGoogle Scholar
  86. 86.
    Marshall PD, Poddar S, Tweed EM, Brandes L. Clinical inquiries: do glucosamine and chondroitin worsen blood sugar control in diabetes? J Fam Pract. 2006;55(12):1091–3.PubMedGoogle Scholar
  87. 87.
    Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Investig. 1994;93(6):2379–86.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Lanham-New SA. Is “vegetarianism” a serious risk factor for osteoporotic fracture? Am J Clin Nutr. 2009;90(4):910–1.CrossRefPubMedGoogle Scholar
  90. 90.
    Puri BK. The safety of evening primrose oil in epilepsy. Prostaglandins Leukot Essent Fatty Acids. 2007;77(2):101–3.CrossRefPubMedGoogle Scholar
  91. 91.
    Shellhaas RA, Barks AK, Joshi SM. Prevalence and risk factors for vitamin D insufficiency among children with epilepsy. Pediatr Neurol. 2010;42(6):422–6.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.CrossRefPubMedGoogle Scholar
  93. 93.
    Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012;32(9):2601–4.CrossRefPubMedGoogle Scholar
  94. 94.
    National centre for complementary and integrative health. Herbs at a Glance. 2016. Available at: https://nccih.nih.gov/health/herbsataglance.htm. Accessed 30 Sept 2016.
  95. 95.
    Arthritis research UK. Complementary and alternative treatments. 2016. Available at: http://www.arthritisresearchuk.org/arthritis-information/complementary-and-alternative-medicines/complementary-therapies.aspx. Accessed 30 Sept 2016.
  96. 96.
    Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2015;74(1):89–95.CrossRefPubMedGoogle Scholar
  97. 97.
    Zurier RB, Rossetti RG, Jacobson EW, DeMarco DM, Liu NY, Temming JE, et al. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum. 1996;39(11):1808–17.CrossRefPubMedGoogle Scholar
  98. 98.
    Watson J, Byars ML, McGill P, Kelman AW. Cytokine and prostaglandin production by monocytes of volunteers and rheumatoid arthritis patients treated with dietary supplements of blackcurrant seed oil. Br J Rheumatol. 1993;32(12):1055–8.CrossRefPubMedGoogle Scholar
  99. 99.
    Belch JJ, Ansell D, Madhok R, O’Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis. 1988;47(2):96–104.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Macfarlane GJ, El-Metwally A, De Silva V, Ernst E, Dowds GL, Moots RJ, et al. Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology. 2011;50(9):1672–83.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Sizheng Zhao
    • 1
  • Fred Otieno
    • 2
  • Asan Akpan
    • 3
  • Robert J. Moots
    • 1
  1. 1.Institute of Ageing and Chronic DiseaseUniversity of Liverpool, Aintree University HospitalLiverpoolUK
  2. 2.Department of MedicineAga Khan University HospitalNairobiKenya
  3. 3.Department of Medicine for the ElderlyAintree University HospitalLiverpoolUK

Personalised recommendations